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The impact of routine surveillance
screening with magnetic resonance
imaging (MRI) to detect tumour recurrence
in children with central nervous system
(CNS) tumours: protocol for a systematic
review and meta-analysis
Caroline Main1* , Simon P. Stevens1, Simon Bailey2, Robert Phillips3, Barry Pizer4, Keith Wheatley1,
Pamela R. Kearns1,5, Martin English5, Sophie Wilne6 and Jayne S. Wilson1
Abstract
Background: The aim of this study is to assess the impact of routine MRI surveillance to detect tumour recurrence
in children with no new neurological signs or symptoms compared with alternative follow-up practices, including
periodic clinical and physical examinations and the use of non-routine imaging upon presentation with disease
signs or symptoms.
Methods: Standard systematic review methods aimed at minimising bias will be employed for study identification,
selection and data extraction. Ten electronic databases have been searched, and further citation searching and
reference checking will be employed. Randomised and non-randomised controlled trials assessing the impact of
routine surveillance MRI to detect tumour recurrence in children with no new neurological signs or symptoms
compared to alternative follow-up schedules including imaging upon presentation with disease signs or symptoms
will be included.
The primary outcome is time to change in therapeutic intervention. Secondary outcomes include overall survival,
surrogate survival outcomes, response rates, diagnostic yield per set of images, adverse events, quality of survival
and validated measures of family psychological functioning and anxiety. Two reviewers will independently screen
and select studies for inclusion. Quality assessment will be undertaken using the Cochrane Collaboration’s tools for
assessing risk of bias. Where possible, data will be summarised using combined estimates of effect for time to
treatment change, survival outcomes and response rates using assumption-free methods. Further sub-group analyses
and meta-regression models will be specified and undertaken to explore potential sources of heterogeneity between
studies within each tumour type if necessary.
(Continued on next page)
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Discussion: Assessment of the impact of surveillance imaging in children with CNS tumours is methodologically
complex. The evidence base is likely to be heterogeneous in terms of imaging protocols, definitions of radiological
response and diagnostic accuracy of tumour recurrence due to changes in imaging technology over time. Furthermore,
the delineation of tumour recurrence from either pseudo-progression or radiation necrosis after radiotherapy is
potentially problematic and linked to the timing of follow-up assessments. However, given the current routine
practice of MRI surveillance in the follow-up of children with CNS tumours in the UK and the resource implications, it is
important to evaluate the cost-benefit profile of this practice.
Systematic review registration: PROSPERO CRD42016036802
Keywords: Children, Central nervous system tumours, Surveillance, Recurrent disease, Magnetic resonance imaging
(MRI), Systematic review
Abbreviations: CNS, Central nervous system—the part of the nervous system consisting of the brain and the spinal
cord; CT, Computerised tomography—radiography in which a three-dimensional image of a body structure is
constructed by computer from a series of plane cross-sectional images made along an axis; HGG, High-grade
glioma—high-grade gliomas encompass the WHO grade III gliomas (anaplastic astrocytoma) and grade IV gliomas
(glioblastome multiforme); LGG, Low-grade gliomas—tumours that exhibit glial differentiation and lack high-grade
findings such as microvascular proliferation and necrosis; MRI, A technique that uses a magnetic field and radio waves
to create detailed images of the organs and tissues within the body
Background
The use of magnetic resonance imaging (MRI) scans in
the diagnosis and management of children with central
nervous system (CNS) tumours is well established [1].
Surveillance scans complement periodic history taking
and physical examination and are undertaken based on
the assumption that a tumour can re-occur before symp-
toms appear and that detection and treatment of recurrent
disease before the development of signs or symptoms may
improve outcome. The scheduling and imaging techniques
used for surveillance protocols are therefore loosely based
on the biological characteristics of the different CNS
tumour types, taking into account the rate of tumour
growth, the location and patterns of local and metastatic
recurrence [2, 3].
Magnetic resonance imaging is a complex modality,
with different sequences (protocols) being used by differ-
ent centres, with the potential for scan results to be in-
determinate. Clinicians face the challenge of diagnosing
and managing patients that have new or old lesions seen
on follow-up MRI and determining whether the lesion is
pseudo-progression, radiation necrosis or tumour recur-
rence. This is further complicated by differences over time
and between centres in radiological response definitions,
complexities of scan interpretation and scan reader inter-
rater reliability.
Obviously, earlier detection and treatment of recurrence
needs to bestow a clinical benefit in terms of reduction in
mortality or an improvement in quality of survival [4] in
order for early detection strategies to be worthwhile, and
further treatment strategies need to be available to balance
the risk-benefit profile of earlier detection. These risks
include the need for sedation or anaesthesia in children,
the negative psychological impact associated with an up-
coming imaging session and the consequent results and,
at a societal level, the direct and in-direct healthcare costs
incurred with surveillance screening and changes in pa-
tient management strategies.
The impact of surveillance imaging has been assessed
in children with different types of malignant CNS tumours
including low- and high-grade gliomas [5–7], medulloblas-
toma [6, 8–10], ependymoma, [11] and central nervous
system primitive neuroectodermal tumours (CNS-PNETs)
[12]. However, differences in imaging schedules and mo-
dalities (including both computerised tomography (CT)
and MRI), and a reliance upon case series studies, mean no
consensus has been reached regarding the utility of surveil-
lance imaging, the optimal interval for undertaking scans
or the length of surveillance following diagnosis. Whilst ap-
propriate assessment of the impact of routine MRI surveil-
lance screening to detect tumour recurrence in children
with either no new, stable or improved neurological signs
or symptoms with malignant CNS tumours is methodo-
logically challenging and needs to be founded on data
from appropriately designed randomised controlled trials
(RCTs), given its current use in the UK, it is important to
assess the cost-benefit of this practice. To date, no system-
atic reviews have been conducted that evaluate the impact
of this screening strategy compared to imaging upon pres-
entation of signs or symptoms of recurrent disease. This
review therefore aims to:
(1)Assess the impact of routine MRI surveillance to
detect tumour recurrence in children with either no
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new, stable or improved neurological signs or
symptoms with CNS tumours compared to
alternative follow-up practices, including periodic
clinical history taking and physical examination and
the use of non-routine imaging upon presentation
with disease signs or symptoms
(2)Where possible, evaluate the effects of varying MRI
screening intervals by tumour type and determine
the optimum length of time for screening post initial
diagnosis
(3)Identify gaps and methodological weaknesses in the
current evidence base to inform the design and
analysis of further RCTs and make
recommendations on the need for further primary
research
Methods
Standard systematic review methodology aimed at mini-
mising bias will be employed, and reporting will follow
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [13]. The
protocol for this review is registered with PROSPERO
(CRD42016036802), available from http://www.crd.york.a-
c.uk/PROSPERO/display_record.asp?ID=CRD42016036802.
The PRISMA for Protocols (PRISMA-P) checklist for
the review is also included as Additional file 1.
Data sources and searches
This review forms part of a wider work programme of
systematic reviews which aim to assess the effects of dif-
ferent interventions for the treatment of CNS tumours
in children, adolescents and young adults. Searches have
therefore been conducted for studies examining the ef-
fects of imaging, surgery, radiotherapy, chemotherapy,
immunotherapy, hormone therapy and biological therap-
ies used alone or as part of a multimodality treatment
regimen for all types of paediatric brain tumours. No
study design filters have been applied to the searches.
Specific details of the searches conducted are detailed
below.
Bibliographic databases
A comprehensive, broad search strategy was developed
using a combination of medical subject headings (MeSH)
and free-text terms. The searches were limited by date
from 1985 to October week 4, 2015. No language or
publication status restrictions were applied, and ongoing
studies were included.
The searches for published studies were undertaken
using the following databases: MEDLINE (OvidSP);
MEDLINE In-Process Citations & Daily Update (OvidSP);
EMBASE (OvidSP); Cochrane Database of Systematic
Reviews (CDSR) (Wiley); Cochrane Central Register of
Controlled Trials (CENTRAL) (Wiley); CINAHL Plus
(EBSCO); DARE (CRD website); and HTA (CRD web-
site). The search strategy used for the MEDLINE search
is reported in Appendix 1.
Grey literature, completed and on-going studies were
identified by searches of NIH Clinical Trials (http://
www.clinicaltrials.gov/); Current Controlled Trials (http://
www.controlled-trials.com/); and WHO International Clin-
ical Trials Registry Platform (ICTRP) (http://www.who.int/
ictrp/en/)
Other sources
Experts in the field, from both the Project Advisory and
Patient and Public Involvement (PPI) Groups, were con-
tacted with a list of identified studies to find out whether
they had knowledge of any further studies that had not
been retrieved by the electronic searches. Reference lists
of all studies included in the present review will be
checked and citation searching undertaken in order to
identify any further studies not retrieved by the elec-
tronic searches.
All identified references have been downloaded into
Endnote X7 software for initial assessment and hand-
ling. Where flexibility is needed throughout the work
programme for reference management and handling,
Endnote software will be linked to bespoke Access da-
tabases in order facilitate sorting and manipulation of
data items within indexed fields and abstracts.
Study selection
All studies have been loosely ‘tagged’ according to the
study design and type of intervention using the seven
intervention categories outlined above. All studies ‘tagged’
as ‘imaging protocols’ will be used to form the potential
pool from which studies will be screened against the spe-
cific inclusion criteria. Study selection will be undertaken
by two reviewers working independently initially using the
titles/abstracts from the pool of potential studies. Studies
marked for inclusion by either reviewer will then undergo
full independent text assessment. Any discrepancies will
be resolved by recourse to the abstracts or full texts or
through consensus with a third reviewer. A PRISMA
flow chart illustrating the study selection process will
be documented [13].
Inclusion/exclusion criteria
Population: Infants, children and young adults (up to
age 25 years) with diagnoses of any type of CNS
tumour that has either no new, stable or improved
neurological signs or symptoms at the time of study
recruitment. These include but are not limited to
high- and low-grade gliomas (HGG and LGG),
medulloblastoma, ependymoma and germ cell tumours.
Studies that include both children and adults within the
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relevant populations will be included provided results are
reported separately for children (defined as up to the
age of 25). Likewise, data from studies including children
with different CNS tumour types will be included
provided that (a) data are reported separately by
tumour type and (b) data are reported for ten or
more participants with a specific type of tumour.
Interventions: Routine interval follow-up MRI scans in
children with either no new, stable or improved
neurological signs or symptoms. These can be conducted
at any screening interval determined within the primary
study and include T2, T1, T1 with contrast, diffusion and
FLAIR images. Studies that do not report the use of a
post-operative MRI scan or use CT as the imaging
modality at baseline will be excluded. Likewise, studies
that use both MRI and CT scans for routine imaging
surveillance will only be included if data are reported
separately for children who underwent MRI scans.
Comparator: Any alternative follow-up schedule, including
the use of periodic clinical history taking and physical
examination and non-routine scheduled MRI scan(s)
conducted due to physical signs/symptoms of tumour
progression or recurrence.
Outcomes: The primary outcome is time to change in
therapeutic intervention. Secondary outcomes are
overall survival, surrogate survival outcomes, response
rates, short- and long-term adverse events, diagnostic
yield per set of images, quality of survival and validated
measures of family psychological functioning and anxiety.
Study designs: Randomised controlled trials (RCTs) and
non-randomised comparative studies. All uncontrolled
study designs and diagnostic test accuracy studies will
be excluded.
Data extraction
Data will be recorded on a standard data extraction form
developed in either Access or Excel. The data will be ex-
tracted by one reviewer and checked by a second for ac-
curacy. Any discrepancies will be resolved by recourse to
the paper. Data from studies with multiple publications
will be extracted and reported as a single study.
Data will be extracted on general (study name, study
group (if applicable), publication date(s), principal
investigator/authors); eligibility and study participants
(e.g. tumour type and location; grade; age, gender,
prior treatment history); definition of radiographic re-
currence and other outcomes; intervention and comparator:
MRI sequencing schedule (including plane(s), weighting,
contrast enhancement; number of scans; scanning intervals;
diagnostic yield per set of images; concomitant therapy);
treatment intent (curative or palliative), study design
(randomised controlled trial or non-randomised compara-
tive study), length of follow-up and timing of outcome as-
sessments; outcome measures (protocol specified, where
available and reported); results (time to change in thera-
peutic intervention; overall survival, surrogate survival
outcomes, response rates, short- and long-term adverse
events, quality of survival and measures of family psycho-
logical functioning and anxiety); analysis methods (ITT or
per protocol) and the author’s conclusions.
Assessment of risk of bias in studies
The quality of RCTs and non-randomised comparative
trials will be assessed using the Cochrane Collaboration’s
risk of bias tool for randomised trials and ROBINS-I,
respectively [14, 15].
Additional criteria will also be used to assess the ad-
equacy of the sample size and methods of analyses and
the likely external validity of the study. All assessment
will be at the overall study level, not at the level of the
individual outcomes. Quality assessment will be under-
taken by one reviewer independently and checked for ac-
curacy by a second. Any disagreements will be resolved by
recourse to the study paper(s) and a third reviewer will be
consulted where necessary. In addition to the methodo-
logical criteria listed above, the GRADE framework may
be used to consider inconsistency between studies,
precision of results, likelihood of publication bias and
applicability of results to population(s) of interest [16].
Data synthesis and analysis
Narrative synthesis
A narrative synthesis of study results will be presented
(including text, figures and tables), to provide adequate
interpretation of study findings. Studies will be grouped
by tumour type, treatment line (induction, consolidation,
salvage) and imaging sequences (where possible). The
outcomes considered include time to change in therapeutic
intervention, overall survival, surrogate survival outcomes,
response rates, diagnostic ‘yield’ rate, quality of survival
and validated measures of family psychological functioning
and anxiety. Therefore, outcomes will be expressed in
terms of hazard ratios (HR; (adjusted or unadjusted)), risk
ratios (RR) and weighted mean differences as appropriate.
All analyses will be conducted per outcome, including all
studies that have reported data for the outcome.
Where more than one RCT has addressed the same
question within the same tumour type and treatment
line, and they are considered to be clinically similar (based
on patient population and imaging protocol), results will
be combined in a standard pairwise meta-analysis using
assumption-free methods. All analyses will be carried out
on an intention-to-treat (ITT) basis where possible, using
the HR or RR as appropriate.
Heterogeneity will be investigated visually using forest
plots and statistically using the I2 and Q statistic [17].
Heterogeneity will be formally investigated using sub-
group analyses and meta-regression where sufficient data
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are available. It is anticipated that the effects of the fol-
lowing variables will be investigated: methodological
quality of the primary studies; tumour type, location
and grade; extent of resection; prior treatments
(chemotherapy/radiotherapy/multimodal regimens); num-
ber of relapses; imaging protocols and imaging intervals.
Other variables considered relevant on further examin-
ation of the literature or input from clinical experts may
also be considered. The coefficient describing the effect of
each variable on the outcome will be modelled, using a
random effects model. All analyses will be conducted
using RevMan (version 5.1) and STATA (STATA™ for
Windows, version 10.1, Stata Corp; College Station, TX).
Assessment of small study effects For each meta-
analysis containing ten or more studies, the likelihood of
small study effects and publication bias, namely the ten-
dency for smaller studies to provide more positive find-
ings, will be assessed using a modified linear regression
test for funnel plot asymmetry as recommended where
there are sufficient numbers of trials (i.e. six trials) [18].
Discussion
The methodology used to conduct this review has been
designed to be robust, comprehensive and minimise
bias. However, it is anticipated there will be a number of
limitations with the review. The assessment of the im-
pact of routine MRI surveillance in children with malig-
nant CNS tumours is complex and presents a number of
methodological challenges. These relate to the natural
history of the tumour types and highly different baseline
risks of progression [19], differences in imaging tech-
nologies and definitions of radiological response between
studies and changes in both of these over time, the type
of imaging protocols and schedules selected and the
complexity of scan interpretation and inter-rater reliabil-
ity. Furthermore, the assessment and measurement of
time from initial diagnosis to change in therapeutic
intervention as the appropriate outcome is important, as
measures of overall or surrogate survival outcomes will
be confounded by changes in the treatment pathway due
to potentially earlier radiological tumour recurrence de-
tection. In terms of time to change in therapeutic inter-
vention, the concepts of lead time and length bias are
well documented in the screening literature [19], with
lead-time bias minimised by measuring this outcome
from initial diagnosis, not from the time of tumour re-
currence [19]. Differences in time to change in thera-
peutic intervention due to recurrence associated with
length bias; whereby longer time to change in therapeutic
intervention may be due to inherent differences in the
baseline tumour characteristics rather than due to earl-
ier detection can be minimised through the use of ad-
equately randomised, and therefore balanced, randomised
controlled trials (RCTs) [19]. Whilst limiting the evidence
base to controlled trials should strengthen the robustness
of the evidence base, it may restrict the breath of the re-
view where no trials for some tumour types or disease
stages are available. This will impact the utility of the re-
view results for informing decision-making on the wider
effectiveness of surveillance MRI screening in children
with CNS tumours. However, given the current routine
practice of MRI surveillance in the follow-up of children
with CNS tumours, it is important to evaluate the cost-
benefit profile of this practice and the impact of different
screening intervals in a methodologically robust manner.
Dissemination
To ensure that our finding have clinical impact on patients,
their parents and the physicians who care for them, results
will be disseminated broadly by presenting at scientific
conferences, published in peer-reviewed journals and
through our Patient and Public Involvement (PPI) Part-
ners who work for established high-profile UK brain
tumour charities and our Clinical Steering Group.
Appendix 1: clinical effectiveness search strategy
MEDLINE (OvidSP): 1985 - October week 4, 2015
1. Glioma/or Brain Neoplasms/or Meningioma/or
Glioblastoma/or Astrocytoma/
2. ((brain or brainstem or intracranial or posterior
fossa) adj3 (cancer* or carcinom* or tumor* or tumour*
or neoplasm*)).mp.
3. (Astrocytoma* or Brain Stem Glioma* or Medullo-
blastoma*or Primitive Neuroectodermal Tumo?r* or
ganglioneuroblastoma* or CNS neuroblastoma* or
Ependymoblastoma or Medulloepithelioma or Pineal
Parenchymal Tumour* or (Atypical Teratoid adj1 tumo?r*)
or Oligoastrocytoma or ((Pilocytic or Gemistocytic)
adj1 astrocytoma*) or ependymoma or primitive neuroec-
tal tumo?r*).mp.
4. (((Diffuse fibrillary or Gemistocytic or Pilocytic
Pilomyxoid Protoplasmic Subependymal giant cell) adj1
astrocytoma*) or Oligoastrocytoma or Oligodendroglioma
or Oligoastrocytoma or Pleomorphic xanthoastrocytoma
or ((astrocytoma or oligoastrocytoma or oligodendrogli-
oma) adj1 astrocytoma*) or Glioblastoma or Gliomatosis
cerebri or Gliosarcoma or ((diffuse intrinsic pontine gli-
oma or low grade brain stem) adj1 glioma) or ((classic
or desmoplastic or nodular or large cell or nodularity)
adj1 medulloblastoma*) or Primitive Neuroectodermal
Tumo?r* or ((ganglioneuroblastoma or neuroblastoma)
adj 1central nervous system*) or Ependymoblastoma or
Pineoblastoma or pineal parenchymal tumo?r* or (central
nervous system adj1 atypical teratoid) or (central nervous
system adj 1 rhabdoid tumo?r*) or Germinomas or
((immature or mature or malignant transformation)
adj2 teratomas)).mp.
Main et al. Systematic Reviews  (2016) 5:143 Page 5 of 7
5. 1 or 2 or 3 or 4
6. exp Surgical Procedures, Operative/
7. surg*.mp.
8. debulk*.mp.
9. cytoreduc*.mp.
10. 6 or 7 or 8 or 9
11. (chemotherap* or antineoplastic agents or cyto-
toxic or alkylating agents or nitrosoureas or antimetab-
olite* or antitumor?r or ((antibod* or monoclonal) adj 3
Human*) or plant alkyloid* or (hormone* adj 1 agent*)
or anthracycline* * or systemic therap*).mp.
12. (Everolimus or Afinitor or Cetuximab or Erbitux
or Bevacizumab or Avastin or Cediranib or Recentin or
lomustine or CCNU or CeeNU or carmustine or BiCNU
or Carustine or Ethylnitrosourea or Streptozocin or So-
rafenib or Nexavar or tipifarnib or Zarnestra or Erlotinib
or Tarceva or Sorafenib or Nexavar or temsirolimus or
Torisel or Sunitinib or Sutent or irinotecan or Campto-
sar or Campto or Vandetanib or Caprelsa or Cabozanti-
nib or Cometriq or XL184 or Axitinib or AG013736 or
Inlyta).mp.
13. 11 or 12
14. exp Immunotherapy/ae, cl, ct, mt, mo, nu, px, st
15. exp Genetic Therapy/ae, cl, ct, mt, mo, nu, ut
16. exp Imaging, Three-Dimensional/or exp Whole
Body Imaging/or exp Magnetic Resonance Imaging/
17. exp Tomography, Emission-Computed/or exp Four-
Dimensional Computed Tomography/or exp Tomog-
raphy/or exp Tomography, Emission-Computed, Single-
Photon/or exp Positron-Emission Tomography/
18. 16 or 17
19. (radiation therapy or radiotherap* or intensity
modulat* radiotherapy*or radiosurgery or radiation on-
cology or reduced boost volume radiotherap* or hyper
fractionat* stereotactic radiotherap*or adjuvant radio-
therap* or body radiotherap* stereotactic*or computer
assisted radiotherap*or computer assisted radiotherap*-
planning or conformal radiotherap* or dosage* radio-
therap* or dose fractionation* radiotherap* or high energy
radiotherap*or implant radiotherap*or intensity or modu-
lated radiotherap*or interstitial radiotherap*orimage
guided radiotherap*or stereotactic*guid* radiotherap* or
local therap* or proton therap* or proton adj2 therap* or
proton beam therap* or proton adj2 radiation or proton
radiation therap* or proton adj2 radiotherap* or proton
adj2 irradia* or PBT).mp.
20. 10 or 13 or 14 or 15 or 18 or 19
21. 5 and 20
22. (Response or overall survival or progression* free
survival or event* free survival or time to recurrence or
time to progression or disease* free interval* or endocri-
nopath* or ((growth or thyroid) adj 1 hormone adj 3
deficienc*) or ((glucocorticoid or gonadotropin) adj 3
deficienc*) or endocrine dysfuct* or (cardiac function*
adj 3 impair*) or ataxia or spastic paresis or visual
dysfunction or epilepsy or hemiparesis or neurolog*
deficit*).mp.
23. 21 and 22
24. limit 23 to (yr = "1985 -Current" and ("newborn in-
fant (birth to 1 month)" or "infant (1 to 23 months)" or
"preschool child (2 to 5 years)" or "child (6 to 12 years)"
or "adolescent (13 to 18 years)" or "young adult (19 to
24 years)") and humans)
Additional file
Additional file 1: PRISMA-P completed checklist for protocol: the impact
of routine surveillance screening with magnetic resonance imaging (MRI) to
detect tumour recurrence in children with central nervous system (CNS)
tumours. (DOCX 17 kb)
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